A Double-Blind, Randomized, Placebo-Controlled, Phase IIa, Multiple Dose, Multicenter Study in Subjects With Mild to Moderate Dementia of the Alzheimer's Type to Evaluate the Safety and Tolerability of Two 10-Week Dose Regimens of Orally-Administered PF-04494700

Trial Profile

A Double-Blind, Randomized, Placebo-Controlled, Phase IIa, Multiple Dose, Multicenter Study in Subjects With Mild to Moderate Dementia of the Alzheimer's Type to Evaluate the Safety and Tolerability of Two 10-Week Dose Regimens of Orally-Administered PF-04494700

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Feb 2010

At a glance

  • Drugs Azeliragon (Primary)
  • Indications Alzheimer's disease; Dementia
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Feb 2010 Endpoint methodology added (where possible).
    • 12 May 2009 Actual end date (Jun 2006) added as reported as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top